Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accounts Payables (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Accounts Payables for 13 consecutive years, with $22.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 19.45% to $22.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.2 million, a 19.45% decrease, with the full-year FY2025 number at $22.2 million, down 19.45% from a year prior.
  • Accounts Payables was $22.2 million for Q4 2025 at Iovance Biotherapeutics, down from $31.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $33.1 million in Q4 2023 to a low of $19.3 million in Q3 2023.
  • A 3-year average of $28.2 million and a median of $29.8 million in 2023 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 10.85% in 2025; the steepest drop was 19.45% in 2025.
  • Iovance Biotherapeutics' Accounts Payables stood at $33.1 million in 2023, then dropped by 16.95% to $27.5 million in 2024, then decreased by 19.45% to $22.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Accounts Payables are $22.2 million (Q4 2025), $31.2 million (Q3 2025), and $32.0 million (Q2 2025).